Screener
BridgeBio Pharma BBIO Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Redeemable convertible noncontrolling interests | (951) | (570) |
| Stockholders’ deficit: | ||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 204,386,699 shares issued and 195,707,702 shares outstanding as of March 31, 2026; 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 | 204 | 202 |
| Treasury stock, at cost; 8,678,997 shares as of March 31, 2026; 7,597,172 shares as of December 31, 2025 | (405,776) | (323,276) |
| Additional paid-in capital | 2,112,454 | 2,057,646 |
| Accumulated other comprehensive income (loss) | (8) | 12 |
| Accumulated deficit | (3,985,237) | (3,821,194) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's common stock par value per share?
- BridgeBio Pharma (BBIO) reported common stock par value per share of $0.00 in Q1 2026.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.
Ask your AI about BridgeBio Pharma's common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude